Corcept Therapeutics Inc
corcept.comCorcept Therapeutics (NASDAQ: CORT) is a pharmaceutical company that develops and markets drugs for serious metabolic, oncologic, and psychiatric disorders. Revenue comes entirely from sales of its cortisol modulation drug Korlym (mifepristone 300 mg), prescribed for hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome. The filing excerpts provided do not contain sufficient detail to characterize market position, competitive set, segment revenue breakdown, unit economics, capital structure, founding history, or leadership with the specificity required for grounded claims.
Products & Services
Korlym (mifepristone 300 mg): cortisol modulator approved for hyperglycemia secondary to hypercortisolism in adults with endogenous Cushing's syndrome.
Revenue Model
Product sales of Korlym (mifepristone 300 mg), a prescription pharmaceutical for Cushing's syndrome. Revenue is transactional, generated per prescription filled.
Customers & Markets
Patients with endogenous Cushing's syndrome; prescribing physicians in endocrinology and related specialties.
Loading...
